CWM
TRVI icon

Curi Wealth Management’s Trevi Therapeutics TRVI Stock Holding History

Curi Wealth Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-998
Closed -$3K – 645
2022
Q2 		$3K Sell
998
-3,746
-79% -$9.2K ﹤0.01% 501
2022
Q1 		$10K Buy
+4,744
New +$4.91K ﹤0.01% 365

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Curi Wealth Management's TRVI Position: Q3 2022 in Review

Curi Wealth Management sold out of Trevi Therapeutics (TRVI) in Q3 2022, closing a stake of 998 shares — an estimated $3K sold.

Curi Wealth Management first reported a position in TRVI in Q1 2022 and held it in 2 quarters. The position peaked at $10K in Q1 2022. 40 funds tracked by Wall St. Rank hold TRVI as of Q3 2022.

  • Curi Wealth Management reported no remaining Trevi Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Curi Wealth Management sold 998 Trevi Therapeutics shares in Q3 2022, an estimated $3K.
  • Curi Wealth Management first reported a position in Trevi Therapeutics in Q1 2022 and held it in 2 quarters.
  • Curi Wealth Management's Trevi Therapeutics position peaked at $10K in Q1 2022.
  • 40 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2022.

Based on Curi Wealth Management's 13F filing for Q3 2022, filed 8 Nov 2022.